EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, APRIL 17, 2017
Media Advisory: To contact corresponding author Florence Gressier, M.D., Ph.D., email firstname.lastname@example.org
To place an electronic embedded link in your story: Links will be live at the embargo time: http://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2017.0124
A new article published by JAMA Pediatrics reviews and analyzes a small collection of studies on fetal exposure to antidepressants and autism spectrum disorders (ASDs).
Florence Gressier, M.D., Ph.D., of the Bicêtre University Hospital, Le Kremlin-Bicêtre, France, and coauthors identified 10 relevant studies with inconsistent results to examine ASDs and fetal exposure to antidepressants during pregnancy for each trimester and during the preconception period.
“Future studies, comprising an assessment of diagnoses, severity of illness and treatments at different stages in pregnancy and substance abuse, are needed and could help disentangle the role of the mother’s psychiatric condition and psychotropic drug use in the risk for ASDs. Further detailed observational data to address these confounding factors are required to investigate the association between antidepressant exposure and ASDs,” the article concludes.
For more details and to read the full study, please visit the For The Media website.
(JAMA Pediatr. Published online April 17, 2017. doi:10.1001/jamapediatrics.2017.0124; available pre-embargo at the For The Media website.)
Editor’s Note: The article contains conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #
For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email email@example.com.